Navigation Links
AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force
Date:11/17/2009

NEW HAVEN, Conn., Nov. 17 /PRNewswire/ -- HistoRx today announced that the Company's proprietary AQUA technology, an automated image analysis platform based on tissue-based quantitative immunofluorescence, was noted in a recent National Comprehensive Cancer Network (NCCN) Task Force Report on hormone receptor testing in breast cancer as one of the "... promising new strategies being developed for the measurement of ER and PgR in breast cancer tissue." Experts from the country's leading cancer treatment institutions responded in the report to growing concerns about hormone receptor testing in breast cancer by standard immunohistochemistry (IHC) methodology, particularly a high false-negative rate, and clarified how such testing can be improved. Hormone receptor testing, which includes estrogen receptor (ER) and progesterone receptor (PgR), is a standard part of the diagnostic characterization of an individual's breast cancer and drives treatment decision making.

"The NCCN Task Force Report demonstrates the growing confidence within oncology circles that AQUA analysis provides a new and promising approach to hormone receptor testing," said Rana K. Gupta, CEO of HistoRx. "We believe the upcoming ASCO-CAP guidelines will reinforce the Task Force's assessment that current methods of ER testing are flawed and will further underscore the need for a better solution. AQUA technology's sensitivity, reproducibility and quantification improve upon standard immunohistochemistry testing and can play an important role in improving the overall accuracy of hormone receptor testing."

An early example of personalized medicine, ER testing and PgR testing are typically performed by standard IHC. AQUA® technology brings standardization and reproducibility to IHC analysis and is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections. This advance enables fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. AQUA's proprietary software uses automated fluorescent image acquisition and data analysis to provide precise quantification of protein biomarkers of interest, including hormone receptors. HistoRx has developed ER and PgR tests based on AQUA® technology. Both of these assays have been used to analyze the TEAM trial, a randomized, international study of more than 9,000 postmenopausal women with hormone sensitive early breast cancer. Results from this analysis will be discussed at the San Antonio Breast Cancer Symposium in December 2009.

[About HistoRx] HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.

SOURCE HistoRx, Inc.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
Breaking Medicine News(10 mins):